Monensin

Summary

Monensin (CHEMBL256105) is an approved small-molecule antifungal agent; with CIViC clinical evidence for 1 variant-indication association (e.g. MYB::NFIB Fusion in doid:0080202).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Precision-oncology evidence (CIViC): 1 variant–indication association
• Chemistry: 670.9 Da · C36H62O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL256105
Name	Monensin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	441145
ChEBI	CHEBI:27617
Molecular formula	C36H62O11
Molecular weight	670.9
InChIKey	GAOZTHIDHYLHMS-KEOBGNEYSA-N

SMILES: CC[C@]1(CC[C@@H](O1)[C@@]2(CC[C@@]3(O2)C[C@@H]([C@H]([C@H](O3)[C@@H](C)[C@H]([C@H](C)C(=O)O)OC)C)O)C)[C@H]4[C@H](C[C@@H](O4)[C@@H]5[C@H](C[C@H]([C@@](O5)(CO)O)C)C)C

IUPAC name: (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-[(2R,5S)-5-ethyl-5-[(2R,3S,5R)-5-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoic acid

ChEBI definition: A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.

Pharmacological roles (ChEBI): coccidiostat, antifungal agent, ionophore.

Also known as: A-3823A, E714, Monensin, Monensina, monensin, monensin A, Monensin A, MONENSIN

Parent form; salt/anhydrous children: CHEMBL5314365

Patent coverage: 5,298 distinct patent families (17,132 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
MYB::NFIB Fusion	DOID:0080202	Sensitivity/Response	Monensin	CIViC D	EID12165

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).